Venclexta (Venetoclax)
venetoclax
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| CLL or SLL | Adults | Monotherapy, or combination with obinutuzumab, rituximab, or acalabrutinib | FDA Approved |
| Newly diagnosed AML | Adults ≥75 years, or with comorbidities precluding intensive induction | Combination with azacitidine, decitabine, or low-dose cytarabine | FDA Approved |
Venetoclax is the first selective BCL-2 inhibitor approved for clinical use. By blocking the anti-apoptotic BCL-2 protein, venetoclax restores programmed cell death in malignant cells that depend on BCL-2 for survival. It works independently of p53 status, making it effective in TP53-mutated and del(17p) CLL. In CLL, venetoclax offers fixed-duration therapy options when combined with anti-CD20 antibodies—a paradigm shift from indefinite BTK inhibitor treatment. In AML, venetoclax combinations have become the standard of care for older or unfit patients. In February 2026, the venetoclax-acalabrutinib combination was approved as the first all-oral, fixed-duration regimen for previously untreated CLL (AMPLIFY trial).
Multiple myeloma: A randomised trial (BELLINI) showed increased mortality when venetoclax was added to bortezomib-dexamethasone in unselected MM patients. Use outside controlled trials is NOT recommended. However, patients with t(11;14) translocation may derive benefit, and investigation continues. Evidence quality: Moderate (negative Phase 3; subgroup hypothesis-generating).
Relapsed/refractory AML: Venetoclax combinations are used beyond the approved treatment-naïve setting in clinical practice. Evidence quality: Moderate (retrospective and early-phase data).
Dosing
CLL/SLL — 5-Week Ramp-Up Schedule (Mandatory for TLS Prevention)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Week 1 | 20 mg QD | Ramp-up phase | Assess TLS risk before first dose; initiate hydration and anti-hyperuricaemics Hospitalise high-risk patients for first doses at 20 mg and 50 mg | |
| Week 2 | 50 mg QD | Ramp-up phase | Monitor blood chemistry at 6–8 h and 24 h post-dose at each dose increase | |
| Week 3 | 100 mg QD | Ramp-up phase | Continue TLS prophylaxis and monitoring | |
| Week 4 | 200 mg QD | Ramp-up phase | Continue TLS prophylaxis and monitoring | |
| Week 5 onward — CLL/SLL maintenance | 400 mg QD | 400 mg QD | 400 mg/day | Full target dose reached; continue per combination regimen schedule Always take with a meal to ensure adequate absorption |
CLL/SLL — Dosing by Combination Regimen
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| CLL/SLL with obinutuzumab (1L) — fixed duration | 20 mg ramp-up | 400 mg QD | 400 mg/day | CLL14 regimen: 12 cycles total; obinutuzumab Cycles 1–6 Fixed-duration: venetoclax stops after Cycle 12 |
| CLL/SLL with rituximab (R/R) — fixed duration | 20 mg ramp-up | 400 mg QD | 400 mg/day | MURANO regimen: venetoclax for 24 months from Cycle 1 Day 1 of rituximab Rituximab starts after reaching 400 mg x 7 days |
| CLL/SLL with acalabrutinib (1L) — fixed duration | 20 mg ramp-up | 400 mg QD | 400 mg/day | AMPLIFY regimen: acalabrutinib 14 cycles; venetoclax starts Cycle 3, continues through Cycle 14 First all-oral fixed-duration CLL regimen (Feb 2026); AMPLIFY trial enrolled patients without del(17p)/TP53 mutation; TLS rate 0.3% in AV arm |
| CLL/SLL monotherapy (any line) | 20 mg ramp-up | 400 mg QD | 400 mg/day | Continue until progression or intolerance |
AML — Dosing with Hypomethylating Agents or Low-Dose Cytarabine
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| AML with azacitidine or decitabine — 3-day ramp-up | 100 mg Day 1 → 200 mg Day 2 → 400 mg Day 3+ | 400 mg QD | 400 mg/day | TLS rate 1.1% with azacitidine at current ramp-up Monitor blood chemistry for TLS at each ramp-up step |
| AML with low-dose cytarabine — 4-day ramp-up | 100 mg Day 1 → 200 mg Day 2 → 400 mg Day 3 → 600 mg Day 4+ | 600 mg QD | 600 mg/day | Higher target dose with LDAC; TLS rate 5.6% Separate from the CLL ramp-up schedule |
TLS is the most important identified risk of venetoclax. With the current 5-week CLL ramp-up, TLS rate is approximately 2%. With older shorter ramp-ups, TLS was 13% with fatal events. Before first dose: assess TLS risk based on tumour burden (lymph node size, ALC) and renal function; initiate oral hydration (1.5–2 L/day); start allopurinol or rasburicase; monitor blood chemistry (potassium, calcium, phosphorus, uric acid, creatinine) at 6–8 h and 24 h after each dose during ramp-up. Hospitalise high-risk patients (any node ≥10 cm, or ALC ≥25 x 109/L with any node ≥5 cm) for enhanced IV hydration and monitoring at the 20 mg and 50 mg dose levels.
Venetoclax must always be taken with a meal. Food increases bioavailability 3–5-fold compared with fasting. Without food, venetoclax exposure is inadequate and treatment may be subtherapeutic. Any meal (low-fat or high-fat) provides adequate absorption enhancement.
Pharmacology
Mechanism of Action
Venetoclax is a first-in-class, selective, orally bioavailable inhibitor of B-cell lymphoma 2 (BCL-2), an anti-apoptotic protein that is overexpressed in many haematologic malignancies. Malignant CLL cells and certain AML blasts depend on BCL-2 to evade programmed cell death. Venetoclax functions as a BH3-mimetic, binding directly to the BH3-binding groove of BCL-2 and displacing pro-apoptotic proteins (BAX, BAK), thereby releasing the intrinsic (mitochondrial) apoptotic pathway and triggering cancer cell death. This mechanism operates independently of TP53/p53 status, which is why venetoclax retains full activity in del(17p) and TP53-mutated CLL—populations historically resistant to chemoimmunotherapy. The potent and rapid cytotoxic effect of venetoclax on BCL-2-dependent cells is also the basis for its tumour lysis syndrome risk, particularly in high-tumour-burden patients at treatment initiation. Venetoclax does not significantly inhibit MCL-1 or BCL-XL at therapeutic concentrations, which accounts for both its selectivity and the rationale for combining it with agents that address these alternative anti-apoptotic pathways.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Tmax 5–8 h (fed); absolute bioavailability ~5.4% fasting, ~18–28% fed (3–5-fold food effect); dose-proportional AUC from 150–800 mg | MUST take with a meal; without food, exposure is subtherapeutic; any meal type is adequate |
| Distribution | Apparent Vd 256–321 L; protein binding >99% (unbound fraction <0.01); blood-to-plasma ratio 0.57 | Highly protein-bound; dialysis ineffective for removal; large volume of distribution |
| Metabolism | Hepatic primarily via CYP3A4/5; M27 major circulating metabolite (inactive); also substrate of P-gp and BCRP | Strong CYP3A4 dependence creates critical interaction risk—ketoconazole increases AUC 6.4-fold; contraindicated with strong CYP3A inhibitors during ramp-up (CLL) |
| Elimination | t½ ~26 h (patients); >99.9% faecal (<0.1% urine); 21% as unchanged drug in faeces; minimal accumulation (ratio 1.3–1.4) | Once-daily dosing appropriate given 26-h half-life; renal excretion negligible; however, reduced CrCl increases TLS risk (not a PK effect) |
Side Effects
Adverse reaction data below reflect CLL/SLL monotherapy (pooled N=352, median treatment 14.5 months) and combination studies. AML data are noted separately where distinct. The safety profile differs substantially between CLL and AML due to underlying disease and concomitant chemotherapy.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Neutropenia | 50–65% | All grades; Grade 3/4 in 63–64% (combination); Grade 4 in 31–33%; febrile neutropenia 4–6% |
| Diarrhea | 40–43% | Usually Grade 1–2; manageable with supportive care |
| Nausea | 21–42% | Usually Grade 1–2; antiemetics rarely needed |
| Upper respiratory tract infection | 36–39% | Most common infection across trials |
| Anaemia | 26–33% | Grade 3/4 in 12–18% in combination settings |
| Fatigue | 21–32% | Usually Grade 1–2 |
| Thrombocytopenia | 21–29% | Grade 3/4 in 15–20% in combination settings |
| Musculoskeletal pain | 29% | Monotherapy data |
| Oedema | 22% | Monotherapy data; usually peripheral |
| Cough | 22% | Monotherapy data |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Febrile neutropenia | 4–6% | Requires urgent evaluation and antibiotics; G-CSF support |
| Pneumonia | 9% | Most frequent serious adverse reaction in both mono and combination therapy |
| Tumour lysis syndrome | 2% | With current 5-week CLL ramp-up; was 13% with older ramp-up; TLS rate 1.1% (AML+azacitidine), 5.6% (AML+LDAC) |
| Sepsis | 5% | Monotherapy data; serious adverse reaction |
| Hypokalemia | 18% | Monitor during ramp-up as part of TLS surveillance |
| Hypophosphataemia | 14% | Electrolyte monitoring essential during initiation |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Tumour lysis syndrome (TLS) | 2% (CLL, current ramp-up); up to 13% with old schedule | 6–8 h after first dose and at each dose increase | Can be fatal; mandatory ramp-up, hydration, anti-hyperuricaemics, electrolyte monitoring; hospitalise high-risk patients; withhold if TLS develops |
| Grade 3/4 neutropenia | 63–64% (CLL combo); 95–100% worsen (AML) | First cycles; recurrent | Monitor CBC; interrupt and resume per dose modification table; G-CSF; antimicrobial prophylaxis |
| Serious infections | Pneumonia 9%; sepsis 5% | Throughout treatment | Withhold for Grade 3/4; treat aggressively; resume at same or reduced dose after resolution |
| Fatal adverse reactions (CLL mono) | 2% | Within 30 days of last dose | Most commonly septic shock |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| AML: venetoclax + acalabrutinib (AMPLIFY) | 7.6% | AE-driven discontinuation of venetoclax in AMPLIFY trial |
| CLL: pneumonia / infections | Most common cause | Serious infections (≥5%) including pneumonia, febrile neutropenia, sepsis |
In AML, baseline neutrophil counts worsened in 95–100% of patients on venetoclax combinations. Neutropenia is expected, recurrent across cycles, and requires active management with G-CSF and dose modification rather than premature discontinuation. Antimicrobial prophylaxis is essential. The dose modification approach differs between CLL and AML—refer to PI Tables 4 (CLL) and 6 (AML) for specific guidance.
Drug Interactions
Venetoclax is predominantly metabolised by CYP3A4/5 and is a substrate of P-gp and BCRP. Its CYP3A4 interaction profile is uniquely critical because increased venetoclax exposure during the ramp-up phase directly escalates TLS risk. Co-administration with ketoconazole increased venetoclax AUC by 6.4-fold and Cmax by 2.3-fold. Strong CYP3A inhibitors are contraindicated during the CLL/SLL ramp-up phase. Venetoclax is also a P-gp and BCRP inhibitor and a weak OATP1B1 inhibitor.
Monitoring
- TLS Blood Chemistry6–8 h + 24 h at each ramp-up dose
RoutinePotassium, calcium, phosphorus, uric acid, creatinine. Monitor at 6–8 h and 24 h after each new dose level during ramp-up. Continue monitoring for 24 h after reaching final dose. Changes can occur as early as 6–8 h after the first 20 mg dose. - Complete Blood CountThroughout treatment
RoutineGrade 3/4 neutropenia in 63–64% (CLL combo); Grade 4 in 31–33%. In AML, counts worsen in 95–100%. Interrupt for severe neutropenia; G-CSF as needed. Resume at same or reduced dose per modification table. - Hydration StatusDuring ramp-up
RoutineEnsure oral hydration 1.5–2 L/day starting 2 days before first dose; IV hydration for high-risk patients. Continue through ramp-up phase. Monitor urine output. - Infection SignsEach visit; ongoing
RoutinePneumonia (9%), febrile neutropenia (4–6%), sepsis (5%). Withhold for Grade 3/4 infection until resolution. Fatal infections have occurred (2% in monotherapy). - Renal FunctionBaseline + ramp-up
RoutineReduced CrCl (<80 mL/min) increases TLS risk. No dose adjustment for renal impairment, but more intensive TLS prophylaxis may be needed. No recommended dose for CrCl <30 mL/min. - Tumour BurdenBaseline (before first dose)
Trigger-basedAssess lymph node size, ALC, and splenomegaly to stratify TLS risk (low / medium / high). Determines need for hospitalisation during initial ramp-up doses. - Pregnancy StatusBefore initiation
Trigger-basedVerify pregnancy status before starting. Contraception required during treatment and for 30 days after last dose. Fetotoxic at 1.2x human exposure in mice.
Contraindications & Cautions
Absolute Contraindications
- Strong CYP3A inhibitors at initiation and during ramp-up (CLL/SLL): The expected dramatic increase in venetoclax exposure poses an unacceptable TLS risk. This is the only listed contraindication in the PI.
Relative Contraindications (Specialist Input Recommended)
- Severe renal impairment (CrCl <30 mL/min): No recommended venetoclax dose has been established. These patients have markedly elevated TLS risk. Specialist-guided risk-benefit assessment is essential.
- Patients requiring dialysis: Venetoclax is unlikely to be removed by dialysis given high protein binding and large volume of distribution.
- Pregnancy: Fetotoxic in mice at exposures 1.2 times the human clinical dose. Effective contraception mandatory during treatment and for 30 days after the last dose.
- Multiple myeloma (outside clinical trials): BELLINI trial demonstrated increased mortality with venetoclax + bortezomib-dexamethasone. Use not recommended outside controlled trials.
Use with Caution
- Reduced renal function (CrCl <80 mL/min): Increased TLS risk; more intensive hydration and monitoring required; no dose adjustment needed.
- High tumour burden (node ≥5 cm + ALC ≥25 x 109/L, or any node ≥10 cm): Hospitalise for enhanced TLS monitoring during initial ramp-up doses.
- Concomitant moderate CYP3A inhibitors or P-gp inhibitors: Dose reduction required; heightened TLS and toxicity risk.
- Severe hepatic impairment: 2-fold higher venetoclax exposure observed; use with increased monitoring.
- Male fertility: Risk to human male fertility based on testicular toxicity (germ cell loss) in dogs at 0.5 times the human AUC exposure.
Tumour lysis syndrome, including fatal events and renal failure requiring dialysis, has occurred in patients treated with venetoclax. TLS can occur as early as 6–8 hours after the first dose. With the current 5-week ramp-up in CLL/SLL, TLS rate is approximately 2%. With an earlier 2–3 week ramp-up, TLS was 13% with deaths and renal failure. The mandatory 5-week ramp-up dosing schedule, anti-hyperuricaemic prophylaxis, adequate hydration, and blood chemistry monitoring at each dose increase are essential to reduce TLS risk. Concomitant use with strong CYP3A inhibitors during ramp-up is contraindicated due to increased venetoclax exposure and TLS risk.
Patient Counselling
Purpose of Therapy
Venetoclax works by blocking a protein called BCL-2 that helps cancer cells survive. By removing this protection, venetoclax allows your body to naturally eliminate the cancer cells. Unlike some cancer treatments, venetoclax may be given for a defined period (fixed-duration) depending on your treatment plan, rather than indefinitely.
How to Take
Take venetoclax once daily at approximately the same time each day with a meal and water. Eating a meal with your dose is essential — without food, the medication is not properly absorbed and will not work effectively. Any meal (breakfast, lunch, or dinner) is fine. Your dose will start low and increase weekly over 5 weeks to reduce risk of a serious side effect called tumour lysis syndrome.
Sources
- Venclexta (venetoclax) tablets prescribing information. AbbVie Inc. / Genentech, Inc. Revised 2024. AbbVie PIPrimary source for all dosing, indications, adverse reactions, warnings, and pharmacokinetic data in this monograph.
- Venclexta Summary of Product Characteristics (SmPC). European Medicines Agency. EMAEuropean regulatory reference providing additional safety and PK data.
- Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236. doi:10.1056/NEJMoa1815281CLL14 trial; established venetoclax-obinutuzumab as fixed-duration frontline standard for comorbid CLL patients.
- Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120. doi:10.1056/NEJMoa1713976MURANO trial; demonstrated superiority of venetoclax-rituximab over BR in relapsed/refractory CLL with fixed-duration treatment.
- DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629. doi:10.1056/NEJMoa2012971VIALE-A trial; established venetoclax-azacitidine as standard of care for unfit/elderly AML patients.
- Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–2145. doi:10.1182/blood.2020004856VIALE-C trial; venetoclax with low-dose cytarabine in AML.
- Brown JR, Seymour JF, Jurczak W, et al. Acalabrutinib and venetoclax versus chemoimmunotherapy for previously untreated CLL. N Engl J Med. 2025;392(8):748–762. doi:10.1056/NEJMoa2409804AMPLIFY trial; basis for the first all-oral fixed-duration CLL regimen (acalabrutinib + venetoclax).
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 2.2026. NCCNPositions venetoclax-based combinations as preferred options for CLL across treatment lines.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. Version 3.2025. NCCNTreatment algorithm for AML including venetoclax-based combinations for older/unfit patients.
- Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–208. doi:10.1038/nm.3048Discovery and preclinical characterisation of venetoclax (ABT-199) as a selective BCL-2 inhibitor with platelet-sparing properties.
- Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322. doi:10.1056/NEJMoa1513257First-in-human Phase 1 dose-finding study establishing the ramp-up schedule and demonstrating clinical activity in CLL.
- Salem AH, Agarwal SK, Dunbar M, et al. Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma. J Clin Pharmacol. 2017;57(4):484–492. doi:10.1002/jcph.821Clinical PK characterisation including food effect, CYP3A interactions, and dose proportionality data.
- Salem AH, Dunbar M, Rusten A, et al. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor. Clin Transl Sci. 2024;17(5):e13807. doi:10.1111/cts.13807Comprehensive PK/PD review covering absorption, metabolism, drug interactions, and exposure-response across malignancies.
- Agarwal SK, Salem AH, Danilov AV, et al. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma. Br J Clin Pharmacol. 2017;83(4):846–854. doi:10.1111/bcp.13175DDI study quantifying the 6.4-fold AUC increase with ketoconazole, supporting the ramp-up contraindication.